NRX Pharmaceuticals Inc. (NRXP)
NASDAQ: NRXPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NRXP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $95.31M
- EPS (TTM)
- -$0.33
- Dividend yield
- None
- 52-week range
- 1.62 – 5.06
- Day range
- 2.14 – 2.53
- Volume / Avg
- 1.47M / 1.07M
- Beta
- —
- Shares outstanding
- 44.33M
52-week range
NRXP stock today
Shares of NRX Pharmaceuticals (NRXP) finished lower on Nov 20 at $2.15, a drop of 15.69% or $0.40 per share, versus the S&P 500's 3.70% decline. At this level, NRXP sits near the bottom of its 52-week range of $1.62 to $5.06: 57.5% below the high, set on Jun 2, 2026 and 32.7% above the low. NRXP is down 20.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 0.9%.
NRX Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.33), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NRX Pharmaceuticals
Company profileNRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jonathan C. Javitt M.D., M.P.H.
- Headquarters
- Wilmington, DE
- Employees
- 29
- IPO year
- 2017
- Website
- nrxpharma.com
Financial highlights
Full financialsIn fiscal 2025, NRX Pharmaceuticals generated $1.2 million in revenue, up 0.0% from fiscal 2024. NRX Pharmaceuticals reported a net loss of $28.6 million, compared with a loss of $25.1 million a year earlier. Gross margin was 58.8% and operating margin -1324.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.23M | $0 | $0 | — | — |
| Growth | — | — | — | — | — |
| Net income | $-28.62M | $-25.13M | $-30.15M | $-39.75M | $-93.06M |
| EPS (diluted) | — | — | — | $-0.60 | $-1.98 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$38.75+1702.33%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.05 vs $-0.29
- Surprise
- +82.76%
NRXP news
All NRXP news- Biotech Stocks On The Rise - AKAN +88%, CUE +49%, ADAG +24%, ANTX +23%, NRXP +10%NasdaqADAG, AKAN, ANTX, CUE
- NRx (NRXP) Q3 2026 Earnings Call TranscriptNasdaq
- NRx Reports Narrower Q3 Loss, Highlights Commercial Launch And Expanding Ketamine Pipeline; Stock UpNasdaqNRXP, ET
- NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue EstimatesNasdaqNRXP, A
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate UpdateGlobeNewswire
- NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running ShortageGlobeNewswire
- NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal DateGlobeNewswire
NRX Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PDSBPDS Biotechnology Corporation | 0.7774 | -3.70% | $95.39M | vs NRXP |
| NBPNovaBridge Biosciences ADR | 0.83 | -5.66% | $96.28M | vs NRXP |
| DERMJourney Medical Corporation | 3.30 | -7.04% | $93.16M | vs NRXP |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs NRXP |
| CLLSCellectis S.A. ADR | 0.9209 | -7.89% | $92.76M | vs NRXP |
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs NRXP |
| CATXPerspective Therapeutics Inc. | 0.7538 | -3.85% | $91.03M | vs NRXP |
| NERVMinerva Neurosciences Inc | 2.00 | -5.66% | $99.67M | vs NRXP |
Indexes, lists and sector
NRX Pharmaceuticals stock FAQ
What is NRX Pharmaceuticals's stock price today?
NRXP last traded at $2.15 as of Nov 20, 4:00 PM EST, down 15.69% on the day. Prices are delayed at least 15 minutes.
Does NRX Pharmaceuticals pay a dividend?
No. NRX Pharmaceuticals does not currently pay a regular cash dividend.
Who is NRX Pharmaceuticals's CEO?
Dr. Jonathan C. Javitt M.D., M.P.H. is the chief executive officer of NRX Pharmaceuticals Inc., which has about 29 employees.
Has NRXP ever split its stock?
Yes. The most recent NRXP stock split was a 1-for-10 split on Apr 2, 2024.
What is the NRXP 52-week high?
The 52-week high for NRXP is $5.06 and the 52-week low is $1.62. The stock is currently 57.5% below its high.